MYND Life Sciences Inc. Announces Collaborative Research Agreement with the University of British Columbia on Major Depressive Disorder

VANCOUVER, BC, Feb. 2, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND") a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce it has signed a Collaborative Research Agreement (the "Agreement") with the University of British Columbia ("UBC") focussing on Major Depressive Disorder ("MDD"), often referred to as depression.

"We are incredibly excited to announce our Collaborative Research Agreement focussing on a treatment for depression," stated Dr. Lyle Oberg, MYND's Chief Executive Officer. "We have an opportunity to improve the wellness and quality of life of people suffering from depression, anxiety and addiction and this agreement helps set the foundation for the development of novel therapies utilizing psilocybin and other related compounds to treat Major Depressive Disorder" continued Dr. Oberg.

The World Health Organization (WHO) states depression is currently estimated to effect more than 264 million people worldwide. Depression and anxiety also contribute $1 Trillion in economic costs globally.¹

"We recognize that traditional pharmaceuticals have not been effective in treating many forms of MDD. We believe that psilocybin has the ability to change the course of depression by working on pathways that we have already identified in prior research," stated Dr. Wilfred Jefferies, MYND's Chief Science Officer. "This Agreement allows my team to expand our research development and delve deeper into the fundamental cause of depression leading to new treatments and diagnostics."

ABOUT MYND LIFE SCIENCES

MYND Life Science Inc. is a leading life sciences company focussed on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on therapeutic approaches to treat diseases of the Central Nervous System using neuroactive agents including psychedelics and other compounds. Research and development is currently underway.

CONTACT INFORMATION
Investor Relations
Email: [email protected] 
Phone: 954-401-8686
Web: www.myndsciences.com

Forward-Looking Information
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.   

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information.

SOURCE Mynd Life Sciences Inc.